Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

About this update from Precision Biosciences, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/837d21d6b29e1a72841066f1c6db2c42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nzX4Drl6qC98Wvz11AQrDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/837d21d6b29e1a72841066f1c6db2c42","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zbiEHBe7H0BW9U4TKw3SPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/837d21d6b29e1a72841066f1c6db2c42","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision’s in vivo gene editing approach","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"- Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing clinical updates anticipated throughout 2025","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"- Received regulatory clearance of IND from the U.S. FDA to expand ELIMINATE-B trial and CTA approved by MHRA for study expansion into the UK. Additionally, PBGENE-HBV granted U.S. FDA Fast Track Designation for chronic Hepatitis B (HBV)","length":237,"tagName":"p","attribs":{}},{"type":"text","content":"- Accelerating PBGENE-DMD within Precision pipeline to be first-in-class in vivo gene editing approach addressing majority of Duchenne’s Muscular dystrophy (DMD) patients; targeting to file IND/CTA in 2025 with clinical data in 2026","length":232,"tagName":"p","attribs":{}},{"type":"text","content":"- Expected cash runway into second half of 2026 enabling data read outs from first two wholly owned in vivo gene editing programs – PBGENE-HBV and PBGENE-DMD","length":157,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., May 15, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the first quarter ended Marc...

More updates from Precision Biosciences, Inc.